Navigation Links
Solta Medical Reports Fourth Quarter and Full Year 2010 Results

HAYWARD, Calif., Feb. 22, 2011 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced results for the fourth quarter and full year ended December 31, 2010. Revenue for the fourth quarter was $30.1 million, an increase of $1.7 million, or 6%, as compared to the fourth quarter of 2009. The improved results for the quarter were driven primarily by a 19% year-over-year increase in sales of treatment tips and consumables.

GAAP net loss for the quarter was $0.2 million as compared to GAAP net loss of $0.3 million reported for the fourth quarter of 2009. Non-GAAP net income was $1.7 million, or $0.03 per diluted share, for both the current quarter and for same period last year. Cash flow generated from operations for the quarter was $3.4 million.

Revenue for the twelve months ended December 31, 2010 grew 12% to $110.9 million, as compared to revenue of $98.8 million for the full year 2009.

The GAAP net loss for the year was $2.0 million, or a loss of $0.03 per share, as compared to a net loss of $11.2 million, or a loss of $0.23 per share reported for the full year 2009. Non-GAAP net income for the full year was $6.8 million, or $0.11 per diluted share as compared to a non-GAAP net loss of $0.8 million, or a loss of $0.02 per share reported for the full year 2009.  Cash flow generated from operations for the full year was $10.2 million.

Solta Medical's GAAP results for the fourth quarter and full year 2010 include non-cash amortization and other acquisition related charges of $1.3 million and $6.3 million, respectively, and non-cash stock based compensation charges of $0.6 million and $2.5 million, respectively. The Company provides additional non-GAAP financial measures that exclude these charges and expenses. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

"Solta accomplished key operational milestones in 2010 under challenging economic conditions. We grew top-line revenue by 12%, expanded our gross margin by more than three percentage points to 63%, produced positive non-GAAP EBITDA every quarter, and generated record cash flow from operations of $10.2 million," said Stephen J. Fanning, Chairman, President & CEO. "Earlier this month, we received positive response to the introduction of our two new products at the American Academy of Dermatology meeting, Clear+Brillant and the Fraxel 1927. In 2011, we will continue to pursue strategic initiatives that address the needs of physicians, clinicians, and consumers with technologies that provide superior aesthetic and therapeutic benefits delivered in a simple, elegant, and cost effective manner. "

Financial Outlook for 2011The company provided a preliminary financial outlook for 2011 as follows:

  • Revenue for the full year 2011 in the range of $118 million to $123 million, representing an increase 6% to 11% from 2010 revenue. The company expects year-over-year revenue growth of high single digits for the first six months of 2011 to be followed by year-over-year revenue growth in the range of 10% to 15% for the last half of 2011. The higher rate of revenue growth in the second half of the year is projected to be driven by the introduction and expanded distribution of products.
  • Non-GAAP gross margin in the range of 66% to 68% for the full year 2011. Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, and acquisition related adjustments. For 2010, the company's non-GAAP gross margin was 66%.
  • Positive non-GAAP EBITDA for every quarter and for the full-year 2011. Non-GAAP EBITDA excludes non-cash amortization charges, non-cash stock based compensation charges, and acquisition related adjustments. For 2010 non-GAAP EBITDA totaled $9.9 million which included a one-time legal settlement gain of $2.2 million.

  • Non-GAAP PresentationTo supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses.  The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results.  This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets.  There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

    Conference Call Information The Company will also host a conference call and webcast today, Tuesday, February 22, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments.  The dial-in number for the conference call is 866-225-8754 for domestic participants and 480-629-9692 for international participants.

    A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers.  Callers will need to use the Passcode 4405060#.  To access the live webcast of the call, go to Solta Medical's website at and click on Investor Relations.  An archived webcast will also be available at  

    About Solta Medical, Inc.Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the only FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, over one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our financial goals for 2011. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-Q for the quarter ended September 30, 2010, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.Solta Medical, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of dollars, except share and per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Net revenue

    $30,066$28,403$110,932$98,818Cost of revenue

    11,79010,97041,40040,565Gross margin

    18,27617,43369,53258,253Operating expenses:Sales and marketing

    11,17810,46042,66538,931Research and development

    3,7944,14216,32416,246General and administrative

    3,6253,09614,62714,659Legal settlement gain

    --(2,213)-Total operating expenses

    18,59717,69871,40369,836Loss from operations

    (321)(265)(1,871)(11,583)Interest and other income

    10530371462Interest and other expense

    (55)(107)(298)(394)Gain on investments

    ---224Loss before income taxes

    (271)(342)(1,798)(11,291)Provision (benefit) for income taxes

    (81)(86)222(99)Net loss

    ($190)($256)($2,020)($11,192)Net loss per share - basic

    ($0.00)($0.01)($0.03)($0.23)Net loss per share - diluted

    ($0.00)($0.01)($0.03)($0.23)Weighted average shares outstanding used in calculating net loss per share:Basic


    59,635,63847,970,14958,908,61147,848,258Solta Medical, Inc.NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE  (in thousands, except share and per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009GAAP Gross margin

    $18,276$17,433$69,532$58,253GAAP gross margin as % of sales

    61%61%63%59%Non-GAAP adjustments to gross margin:GAAP Gross margin

    $18,276$17,433$69,532$58,253Amortization and other non-cash acquisition related charges

    8838383,8255,757Stock-based compensation

    6266270241Non-GAAP gross margin

    $19,221$18,337$73,627$64,251Non-GAAP gross margin as % of sales

    64%65%66%65%GAAP loss from operations

    ($321)($265)($1,871)($11,583)Non-GAAP adjustments to net loss from operations:Amortization and other non-cash acquisition related charges

    1,2151,1735,1577,077Severance expenses

    --55118Acquisition-related expenses

    109-1,087-Stock-based compensation

    5797682,5023,244Non-GAAP income (loss) from operations

    $1,582$1,676$6,930($1,144)Depreciation expenses

    7816632,9262,708Non-GAAP EBITDA

    $2,363$2,339$9,856$1,564GAAP net loss($190)($256)($2,020)($11,192)Non-GAAP adjustments to net loss:Amortization and other non-cash acquisition related charges

    1,2151,1735,1577,077Severance expenses

    --55118Acquisition-related expenses

    109-1,087-Stock-based compensation

    5797682,5023,244Non-GAAP net income (loss)

    $1,713$1,685$6,781($753)GAAP basic net loss per share

    ($0.00)($0.01)($0.03)($0.23)Non-GAAP adjustments to basic loss per share:Amortization and other non-cash acquisition related charges

    $0.02$0.02$0.09$0.15Severance expenses

    $0.00-$0.00$0.00Acquisition-related expenses

    $0.00-$0.02-Stock-based compensation

    $0.01$0.02$0.04$0.07Non-GAAP basic net income (loss) per share

    $0.03$0.04$0.12($0.02)Non-GAAP diluted net income (loss) per share

    $0.03$0.03$0.11($0.02)GAAP weighted average shares outstanding used in calculating basic net loss per share

    59,635,63847,970,14958,908,61147,848,258GAAP weighted average shares outstanding used in calculating diluted net loss per share

    59,635,63847,970,14958,908,61147,848,258Adjustments for dilutive potential common stock

    2,510,1971,770,5252,056,496-Weighted average shares outstanding used in calculating non-GAAP diluted net income (loss) per share

    62,145,83549,740,67460,965,10747,848,258Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)December 31,December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

    $36,898$14,744Accounts receivable


    10,54914,117Prepaid expenses and other current assets

    5,9064,748Total current assets

    65,77945,990Property and equipment, net

    6,2275,613Purchased intangible assets, net


    49,48147,289Other assets

    249458Total assets

    $158,545$136,149LIABILITIES AND STOCKHOLDERS’ EQUITYLiabilities:Accounts payable

    $6,358$6,065Accrued liabilities

    12,03010,968Current portion of deferred revenue

    3,4284,534Short-term borrowings

    9,5289,432Customer deposits

    441529Total current liabilities

    31,78531,528Deferred revenue, net of current portion

    969612Term loan, net of current portion

    981,626Non-current tax liabilities

    3,3721,862Other  liabilities

    177284Total liabilities

    36,40135,912Stockholders’ equity:Common stock, $0.001 par value:100,000,000 shares authorized 59,728,410 and 48,077,028 shares issued and outstanding at December 31, 2010 and December 31, 2009

    6048Additional paid-in capital

    193,198169,283Accumulated deficit

    (71,114)(69,094)Total stockholders’ equity

    122,144100,237Total liabilities and stockholders’ equity


    SOURCE Solta Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System
    2. Solta Medical Donates Fraxel re:store(R) Laser System to Grossman Burn Foundation
    3. Solta Medical Announces New Fraxel re:store(R) Dual Laser System, Receives CE Mark for European Market
    4. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
    5. Solta Medical to Participate in 2nd Annual Lazard Capital Markets Medical Technology Conference
    6. Solta Medical and Alma Lasers Resolve Patent Lawsuits
    7. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
    8. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
    9. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
    10. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
    11. Solta Medical Announces FDA 510(k) Clearance of Fraxel re:store Dual Laser System for the Treatment of Actinic Keratosis
    Post Your Comments:
    (Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
    (Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
    (Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
    Breaking Medicine Technology:
    (Date:11/27/2015)... ... 27, 2015 , ... A team of Swiss doctors has released a report ... has just posted the findings on the website. Click here to read the ... 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the ...
    (Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
    (Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
    (Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
    (Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
    Breaking Medicine News(10 mins):